Skip to content

Impact of the COVID-19 Pandemic in Gynecological Oncology

Impact of the COVID-19 Pandemic on Changes in Therapeutic Strategies in Gynecological Oncology

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04351139
Acronym
COVID-GYN
Enrollment
205
Registered
2020-04-17
Start date
2020-05-06
Completion date
2020-11-30
Last updated
2021-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasm Female, Gynecologic Cancer, Ovarian Neoplasms, Uterine Cervical Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Keywords

Gynecologic Cancer, COVID-19

Brief summary

The current infection with the Coronavirus SARS-CoV-2 (COVID-19) is an exceptional health situation which requires an adaptation of our management practices in gynecological oncology. Data from the literature suggest that infection with Coronavirus is serious in subjects with cancer with a risk of severe form 5 times higher than that of the population without cancer and a risk of death multiplied by 8. In addition, the risk of infection would be 3 times greater in case of cancer. Faced with the COVID-19 epidemic, the investigator must organize themselves to ensure continuity in the treatment of patients with gynecological cancer but also adapt our practices in the management (CPR, teleconsultation, adaptation of treatment or even postponement of treatment). The objective of the High Council of Public Health is to be able to ensure adequate oncological care avoiding any potential loss of chance concerning the care of cancer: people affected must, despite the pandemic, have care allowing the same level of curability (localized cancers) or the same life expectancy (advanced cancers). This must be done by limiting as much as possible the impact on the organization of the service, the organization of patient follow-up and the psychological impact that these possible modifications could have. The hypotheses of our study are that the exceptional health situation linked to this pandemic leads to a change in the care of patients with gynecological cancer associated with a psychological impact and increased anxiety of patients during their care. Despite the extent of the pandemic, very little existing data makes it possible to define recommendations with a sufficient level of evidence.

Interventions

OTHERmodification of the planned therapeutic management

to evaluate the changes in therapeutic management, during the COVID-19 pandemic, of patients suffering from gynecological cancers

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
OTHER

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* women over 18 * gynecological cancer (breast cancer, uterus, ovary, cervix, vagina or vulva cancer) * therapeutic management planned during quarantine * person having expressed his non-opposition Inclusion Criteria of control group : * women over 18 * gynecological cancer (breast, uterus, ovary, cervix, vagina or vulva cancer) * therapeutic management planned on the end of the year 2019 * person having expressed his non-opposition

Exclusion criteria

* inability to understand the information given * person deprived of liberty, * person under guardianship.

Design outcomes

Primary

MeasureTime frameDescription
percentage of patients with a change in the planned therapeutic management (surgery, chemotherapy, radiotherapy, hormone therapy)Day Omodification of the planned therapeutic management

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026